International webinar onPharmaceutical Chemistry and Sciences
Early Bird Registration End Date: Jan 31, 2025
Abstract Submission Opens: Dec 19, 2024
Terms and Conditions
Thank you for your interest in our Sciconx webinar. Please carefully review the following terms and conditions regarding registration, refunds, and other important details:
Substitutions of registered participants for the Sciconx webinar can be made with written notification to the provided email address at least 24 hours before the webinar.
The organizers are not responsible for technical issues experienced by participants during the Sciconx webinar, including but not limited to internet connectivity problems.
The organizers reserve the right to modify these terms and conditions for Sciconx webinars. Any changes will be communicated to registered participants.
By registering for the Sciconx webinar, you acknowledge and accept these terms and conditions. If you have any questions or concerns, please contact us at the provided email address. We look forward to your participation in the Sciconx webinar.
As drug companies fret over their finances, they are increasingly partnering with universities to help with early-stage research
2024-10-07 - 2024-12
Pharmaceutical companies are often lambasted for rising drug costs. For example, the price of new drugs entering the US market in 2023 was 35% higher than in 2022. According to an analysis from Reuters, part of the increase is due to a move to develop therapies for rare diseases: because fewer people have those condition, drug makers push up the per-dose price to recover their costs. But the cost of developing drugs for more common diseases, including cancers, is also rising rapidly.
AstraZeneca's £450 Million Vaccine Facility Faces Delays
2025-01-20 - 2025-01
AstraZeneca's planned £450 million investment in a new flu vaccine facility in Speke, Liverpool, has encountered setbacks due to delays in securing government support. Despite urgent warnings from the UK chairman to Business Secretary Jonathan Reynolds after Labour's election victory, early assurances regarding the government's advanced manufacturing plan were not provided promptly. Consequently, the project's timelines were affected, necessitating reworking to meet tight launch projections. The delays have led to frustration with the Whitehall process. The company had been seeking incentives and support to proceed with the investment. With AstraZeneca's significant contribution to the UK's life sciences sector and economy—being the largest private sector investor in UK R&D and employing around 8,700 people—the delays have put pressure on the government to secure private sector investment for economic growth. The government asserts its commitment to supporting innovative medicine development and is in active discussions with AstraZeneca.
AI and Large Language Models Transforming Pharma
2025-01-05 - 2025-01
A recent study highlights the transformative potential of artificial intelligence (AI) and large language models (LLMs) in the pharmaceutical industry. AI applications span various operational areas, including research and development, clinical trials, production, regulatory affairs, and quality control. Machine learning algorithms, in particular, are contributing to advancements in drug discovery and development, offering promising avenues for innovation and efficiency.
